Overview

Efficacy Study of Glucagonlike Peptide-1 to Treat Reperfusion Injury

Status:
Unknown status
Trial end date:
2016-03-01
Target enrollment:
Participant gender:
Summary
The investigators planned to research the cardioprotective effects of intravenous liraglutide on reperfusion injury.
Phase:
N/A
Details
Lead Sponsor:
Chen Wei Ren, MD
Treatments:
Glucagon
Glucagon-Like Peptide 1
Liraglutide